MedTrace Logo

Safety and Efficacy of Autologous Endothelial Progenitor Cell CD 133 for Therapeutic Angiogenesis

NCT00694642 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2013-08-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether transendocardial injections of autologous endothelial progenitor cells CD 133 is safe and feasible in patients with refractory angina.

Conditions

Interventions

BIOLOGICAL

Selected CD 133+ cells

Endothelial progenitor cell CD 133

Sponsors & Collaborators

  • Fundación Mutua Madrileña

    collaborator OTHER

  • Pilar Jimenez Quevedo

    lead OTHER

Principal Investigators

  • Pilar Jimenez-Quevedo, MD,PhD · Hostpial Clinico San Carlos

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-05-31
Completion
2012-02-29

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00694642 on ClinicalTrials.gov